Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC cuts forecasts for Anglo American on weaker copper outlook

(Sharecast News) - RBC Capital Markets has cut its target price for Anglo American from 2,200p to 2,130p and kept an 'underperform' stance on the stock after downgrading its profit forecasts for the next three years. The move follows Anglo's fourth-quarter production update on Thursday. While the company met guidance across all commodities, 2025-2027 guidance was disappointing, according to RBC.

For copper operations in particular, solid output in the fourth quarter was offset by weaker-than-expected pricing, while the volume outlook for 2027 was underwhelming, the broker said.

"We see downgrades to our 2024-2026 EBITDA of 2%-4%. 2027 EBITDA is down 14%, as our copper assumptions were too optimistic on recovery in volumes at Los Bronces and throughput increase at Quellaveco. We have cut 2027E copper production to 797kt from 964kt to bring it inline with guidance of 760-820kt (Visible Alpha consensus at 835kt)," RBC said.

Anglo shares are now trading at 1.19 times net asset value, a premium to diversified mining peers which have an average price-to-NAV ratio of 1.04, the broker said.

At current prices, RBC added that Anglo is likely not currently a bid target for BHP - following a rejected takeover from the latter last May - trading at just a 2.5% discount to the final offer BHP made in May 2024.

Anglo's stock was up 0.7% at 2,467.5p by 1017 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.